Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1380 Non-clinical results and design of first-in-human study for GIGA-564, a third-generation anti-CTLA-4 monoclonal antibody
Compose a Response to This Article
Other responses
No responses have been published for this article.
